- Home
- TBRG vs IPHA Comparison
TBRG vs IPHA Comparison
Compare TBRG & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TBRG
- IPHA
- Stock Information
- Founded
- TBRG 1979
- IPHA 1999
- Country
- TBRG United States
- IPHA France
- Employees
- TBRG N/A
- IPHA N/A
- Industry
- TBRG
- IPHA Biotechnology: Pharmaceutical Preparations
- Sector
- TBRG
- IPHA Health Care
- Exchange
- TBRG NYSE
- IPHA Nasdaq
- Market Cap
- TBRG 186.6M
- IPHA 191.0M
- IPO Year
- TBRG N/A
- IPHA 2019
- Fundamental
- Price
- TBRG $12.35
- IPHA $2.28
- Analyst Decision
- TBRG Buy
- IPHA Strong Buy
- Analyst Count
- TBRG 2
- IPHA 1
- Target Price
- TBRG $13.50
- IPHA $11.50
- AVG Volume (30 Days)
- TBRG 57.4K
- IPHA 5.5K
- Earning Date
- TBRG 11-06-2024
- IPHA 09-12-2024
- Dividend Yield
- TBRG N/A
- IPHA N/A
- EPS Growth
- TBRG N/A
- IPHA N/A
- EPS
- TBRG N/A
- IPHA N/A
- Revenue
- TBRG $336,557,000.00
- IPHA $36,202,722.00
- Revenue This Year
- TBRG $0.94
- IPHA N/A
- Revenue Next Year
- TBRG $4.58
- IPHA $105.84
- P/E Ratio
- TBRG N/A
- IPHA N/A
- Revenue Growth
- TBRG N/A
- IPHA 6.88
- 52 Week Low
- TBRG $7.55
- IPHA $1.81
- 52 Week High
- TBRG $17.28
- IPHA $3.15
- Technical
- Relative Strength Index (RSI)
- TBRG 48.70
- IPHA 50.55
- Support Level
- TBRG $11.77
- IPHA $2.27
- Resistance Level
- TBRG $12.84
- IPHA $2.41
- Average True Range (ATR)
- TBRG 0.40
- IPHA 0.11
- MACD
- TBRG -0.10
- IPHA -0.00
- Stochastic Oscillator
- TBRG 20.54
- IPHA 52.94
About TBRG TRUBRIDGE INC
TruBridge Inc is a provider of healthcare solutions and services for community hospitals, clinics, and other healthcare systems. It provides services such as Electronic health records & information systems, revenue cycle management, population health, and data management, etc. The segments of the company are RCM, EHR, and Patient Engagement. The company derives maximum revenue from the RCM segment.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.